Pierre Fabre adds to case for triple therapy in BRAF-mutant mCRC

French drugmaker Pierre Fabre and its partner Array BioPharma (Nasdaq: ARRY) have added to the data set supporting a triple combination in BRAFV600E-mutant metastatic colorectal cancer (mCRC).

The triplet of Braftovi (encorafenib), a BRAF inhibitor, Mektovi (binimetinib), a MEK inhibitor and Erbitux (cetuximab), an anti-EGFR antibody, has already been granted Breakthrough Therapy designation by the US Food and Drug Administration (FDA) in BRAFV600E-mutant mCRC as detected by an FDA-approved test, after failure of one to two prior lines of therapy for metastatic disease.

Newly-presented results from the Phase III BEACON CRC trial showed that mature median overall survival was 15.3 months for patients treated with the triplet combination therapy, a marked improvement in comparison with the current standards of care.